Correction: Bar-Sela et al. Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome. Cancers 2020, 12, 2447

Gil Bar-Sela, Idan Cohen, Salvatore Campisi-Pinto, Gil M. Lewitus, Lanuel Oz-Ari, Ayellet Jehassi, Avivit Peer, Ilit Turgeman, Olga Vernicova, Paula Berman, Mira Wollner, Mor Moskovitz, David Meiri

Research output: Contribution to journalComment/debate

Abstract

Error in Table In the original article [1], there was a mistake in Table 1 as published. Typing errors were made regarding demographics and medical conditions data. The corrected Table 1 appears below. Table 1. Demographics and medical conditions. Characteristics Cannabis Non-Users N = 68 Cannabis Users N = 34 Age in years median (range) 69 (18–92) 66 (37–85) p-Value Gender—N (%) Female 22 (32.4) 10 (29.5) Male 46 (67.6) 24 (70.5) 0.9399 Performance Status Eastern Cooperative Oncology Group (ECOG)—N (%) 1≤ 55 (80.8) 24 (70.5) 0.3568 ≥2 13 (19.1) 10 (29.4) 0.3568 Chronic diseases per patient—N (%) 0 22 (32.3) 13 (22.0) 0.7124 1 16 (23.5) 7 (20.5) 0.9332 2 or more 30 (44.1) 14 (41.1) 0.9437 Background diseases—N (%) Chronic heart disease 18 (26.4) 5 (14.7) 0.2762 Diabetes 17 (25.0) 6 (17.6) 0.5576 High blood pressure 34 (50.0) 13 (34.1) 0.3612 Chronic obstructive pulmonary disease (COPD) 9 (13.2) 3 (8.8) 1 Hyperlipidemia 23 (33.8) 7 (20.5) 0.2491 Other 2 (2.9) 0 (0.0) 1 Type of malignancy—N (%) Non-small cell lung cancer 37 (54.4) 20 (58.8) 0.8325 Melanoma 25 (36.7) 9 (26.4) 0.414 Renal cell carcinoma 4 (5.8) 2 (5.8) 1 Other 2 (2.9) 3 (8.8) 1 Main site of metastasis—N (%) Brain 12 (17.6) 8 (13.2) 0.6593 Lungs 39 (57.3) 23 (67.6) 0.4303 Liver 13 (19.1) 11 (32.3) 0.2157 Table 1. Cont. Characteristics Cannabis Non-Users N = 68 Cannabis Users N = 34 p-Value Immunotherapy given as—N (%) First line of treatment 31 (45.5) 8 (23.5) 0.05178 Second line of treatment or more 37 (54.4) 26 (76.4) 0.05178 Checkpoint therapy—N (%) Anti PD1: Pembrolizumab or Nivolumab 47 (69.1) 29 (85.2) 0.127 Ipilimumab and Nivolumab 16 (23.5) 4 (11.7) 0.2517 Anti PDL-1: Durvalumab or Atezolizumab 5 (7.3) 1 (2.9) 1 The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original article has been updated.

Original languageEnglish
Article number1957
JournalCancers
Volume14
Issue number8
DOIs
StatePublished - 1 Apr 2022
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Correction: Bar-Sela et al. Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome. Cancers 2020, 12, 2447'. Together they form a unique fingerprint.

Cite this